Karen Andersen, CFA, is a healthcare strategist for Morningstar Research Services LLC, a wholly owned subsidiary of Morningstar, Inc. She is r ...

Welcome to the Moderna fourth quarter 2024 conference call. At this time, all participants are in a listen-only mode. After ...

MRNA's competitive landscape, particularly against Pfizer, and higher forward P/S ratio suggest the stock is overvalued and ...

Moderna Inc . (BMV:MRNA) reported its fourth-quarter earnings for 2024, revealing a significant decline in revenue and a net loss. The company's earnings per share (EPS) were lower than expected, and ...

Moderna Inc. reported a wider-than-expected fourth-quarter loss on Wednesday, as the biotech company grapples with declining COVID-19 vaccine sales and ongoing restructuring costs. The vaccine maker ...